Intestinal transplantation in humans under FK 506.

Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients.

FK 506 is a new macrolide with potent immunosuppressive activity. Use of this drug is associated with reduced incidence of rejection following liver. kidney. and heart transplantation. 1-4 Recently, FK 506 has been shown to be effective in small bowel transplantation. S It is known that FK 506 absorption is not influenced by the presence or absence of bile.6--8 The aims of this study are to: (\...

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease.

Small intestine allotransplantation in humans is not yet feasible due to the failure of the current methods of immunosuppression. FK-506, a powerful new immunosuppressive agent that is synergistic with cyclosporine, allows long-term survival of recipients of cardiac, renal, and hepatic allografts. This study compares the effects of FK-506 and cyclosporine on host survival, graft rejection, and ...

FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats.

TRANSPLANTED pancreatic islet tissue has been shown to restore normoglycemia and prevent the development of chronic complications in diabetic animals. 1 The application of alloand xenotransplantation of pancreatic islets for the treatment of diabetes is hindered by immune rejection. FK 506, a new immunosuppressive agent, has been demonstrated to be effective in the prolongation of survival of h...

Pharmacokinetics of FK 506: preclinical and clinical studies.

FK 506 is a macrolide with potent immunosuppressive effects. Its immunosuppressive property has been documented in both in vitro! lymphocyte proliferation studies and in vivo studies. FK 506 treatment significantly prolongs graft survival in rats receiving heterotopic heart transplants. dogs receiving kidneys or livers. and baboons receiving kidney transplants.2 Currently, FK 506 is undergoing ...

Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression.